What is Ibuprofen Lysine Market?
This is the medication that is available in the form of injections as well as tablets. The medications belong to the group of medicines called non-steroidal anti-inflammatory medicines which treat pain relief and reduces swelling. It can be used to treat rheumatic or muscular pain, backache, migraine, headache, dental pain, and few other symptoms of cold and flu. This medication can also be taken by adults and adolescents who are between the age of 12-18 years. However, the medicine should only be consumed on the advice of the doctor. These tablets are pain relievers as well as they work as an anti-inflammatory. Ibuprofen lysine usually works more quickly than regular ibuprofen, as itís thought that this type of ibuprofen is absorbed more quickly by your body. There are some side effects that are caused by the intake of ibuprofen that would be skin rashes, tiredness, headache.
The market study is being classified, by Application (Adults and Children) and major geographies with country level break-up.
Strides Shasun Limited (India), Olon Spa (Italy), Dipharma (Italy), BASF (Germany), Solara Active Pharma Sciences (India), Sanofi Active Ingredient Solution (France) and Lundbeck (Denmark) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that European Players will contribute to the maximum growth of Global Ibuprofen Lysine market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Ibuprofen Lysine market by Type, Application and Region.
On the basis of geography, the market of Ibuprofen Lysine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Geriatric Population
- Increasing Adoption of Painkillers in Acute Pain Conditions
- Huge demand in the market with Minimum Competition
- Adoption of Ibuprofen for Treating Mild Symptoms
- Adoption of Ibuprofens with Minimized Cardiovascular Side Effects
- Side Effects Caused by Drugs
- Growing Improvements and Developments Across the Healthcare Industry
- Lack of Awareness about the Ibuprofen Lysine
Market Leaders and some development strategies
In 2018, BASF has acquired Bayer. This acquisition had thereby enhanced the innovation potential and agricultural solutions.
"The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has said that patients taking ibuprofen at doses of 2,400 mg or more per day are at a higher risk of heart attack or stroke than those taking lower doses." and "Practs Committee had stated that the level of risk will not increase when taking up to 1,200 mg of ibuprofen, which is typically the highest recommended dose for OTC versions."
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Ibuprofen Lysine, Suppliers and Distributors of Ibuprofen Lysine, Venture Capitalists and Private Equity Firms and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase